Klebsiella antigens

US8236326B2 · kind B2 · utility

Assignee

• Intercell AG · AT

Inventors

• Sharmila Bakshi · Wien, AT
• Thomas Cipps · Wien, AT
• Markus Hanner · Pressbaum, AT
• Jutta Pikalo · Strau, AT
• Christina Satke · Weitensfeld im Gurktal, AT
• Eszter Nagy · Wien, AT
• Urban Lundberg · Wien, AT
• Dagmar Zierer · Wien, AT
• Andreas Meinke · Pressbaum, AT
• Birgit Noiges · Wien, AT
• Ulrike Stierschneider · Wien, AT
• Alexander Von Gabain · Wien, AT

Key dates

• Filing date: Apr 29, 2008
• Grant date: Aug 7, 2012
• Expiry date: May 3, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/21
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to isolated nucleic acid molecules which encode an antigen, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a Klebsiella species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell, which expresses such antigen. Moreover, the present invention provides antibodies binding to such antigen, a hybridoma cell producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of reducing or inhibiting the interaction activity of such antigen, methods for diagnosing an infection and methods for the treatment or prevention of an infection. More specifically such antigens are produced by or associated with bacterial pathogens causing nosocomial infections or bacterial infections caused by Klebsiella pneumoniae.